CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquires Argenta and BioFocus (CRO services division of Galapagos NV)
Snapshot
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired Argenta and BioFocus (CRO services division of Galapagos NV) for €129 million in cash (plus up to €5 million in future performance payments) in March 2014. The transaction was structured as all cash. Argenta and BioFocus (CRO services division of Galapagos NV) is a United Kingdom (plus certain Dutch assets)-based Discovery and Safety Assessment (DSA) — Early Discovery business.
- Acquirer
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- Target
- Argenta and BioFocus (CRO services division of Galapagos NV)
- Value
- €129 million in cash (plus up to €5 million in future performance payments)
- Date
- March 2014
- Type
- full acquisition
- Status
- ready
The deal at a glance
About this deal
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired Argenta and BioFocus (CRO services division of Galapagos NV) for €129 million in cash (plus up to €5 million in future performance payments), a transaction completed in March 2014, structured as all cash.
Argenta and BioFocus (CRO services division of Galapagos NV) operates in Discovery and Safety Assessment (DSA) — Early Discovery, is based in United Kingdom (plus certain Dutch assets). Argenta and BioFocus, the CRO services division of Galapagos NV, were UK-based global leaders in integrated drug discovery services with a predominant focus on in vitro capabilities. They formed the core of Charles River's Early Discovery business.
On March 31, 2014, the Company completed the previously announced acquisition of the CRO services division of Galapagos NV, which includes both the Argenta and BioFocus businesses. The purchase price was €129 million in cash, subject to certain post-closing working capital adjustments.
Early Discovery business, DSA segment
No advisory firms have been disclosed for this transaction.